WO2007053352A3 - Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands - Google Patents

Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands Download PDF

Info

Publication number
WO2007053352A3
WO2007053352A3 PCT/US2006/041332 US2006041332W WO2007053352A3 WO 2007053352 A3 WO2007053352 A3 WO 2007053352A3 US 2006041332 W US2006041332 W US 2006041332W WO 2007053352 A3 WO2007053352 A3 WO 2007053352A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrroloquinolinone
hydroxytryptamine
ligands
derivatives
receptor
Prior art date
Application number
PCT/US2006/041332
Other languages
French (fr)
Other versions
WO2007053352A2 (en
Inventor
Michael Gerard Kelly
Steven Edward Lenicek
Yvette Latko Palmer
Original Assignee
Wyeth Corp
Michael Gerard Kelly
Steven Edward Lenicek
Yvette Latko Palmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Michael Gerard Kelly, Steven Edward Lenicek, Yvette Latko Palmer filed Critical Wyeth Corp
Publication of WO2007053352A2 publication Critical patent/WO2007053352A2/en
Publication of WO2007053352A3 publication Critical patent/WO2007053352A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a compound of formula (I) and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
PCT/US2006/041332 2005-10-28 2006-10-23 Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands WO2007053352A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73112705P 2005-10-28 2005-10-28
US60/731,127 2005-10-28

Publications (2)

Publication Number Publication Date
WO2007053352A2 WO2007053352A2 (en) 2007-05-10
WO2007053352A3 true WO2007053352A3 (en) 2007-06-28

Family

ID=37905692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041332 WO2007053352A2 (en) 2005-10-28 2006-10-23 Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands

Country Status (1)

Country Link
WO (1) WO2007053352A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505418A (en) * 2007-12-04 2011-02-24 メルク・シャープ・エンド・ドーム・コーポレイション Tryptamine sulfonamide as 5-HT6 antagonist
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
CN103524431B (en) * 2013-09-24 2016-01-13 西安交通大学 3-benzyl-4-quianzolinones and synthetic method thereof and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105081A1 (en) * 2000-08-07 2003-06-05 Daniel Yohannes Heterocyclic compounds as ligands of the GABAA receptor
US20030171295A1 (en) * 1996-06-10 2003-09-11 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171295A1 (en) * 1996-06-10 2003-09-11 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US20030105081A1 (en) * 2000-08-07 2003-06-05 Daniel Yohannes Heterocyclic compounds as ligands of the GABAA receptor

Also Published As

Publication number Publication date
WO2007053352A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
MX2009005358A (en) 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
NO20050007L (en) 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
PL1979355T3 (en) Spiro imidazole derivatives as ppar modulators
MX2009006704A (en) New compounds.
NO20050014L (en) 1-Heterocyclylalkyl-3-sulfonylindole or indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002051837A3 (en) Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
SI2176252T1 (en) 2, 3-dihydrobenzoš1, 4ćdioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MXPA04005886A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands.
MXPA06000701A (en) Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands.
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
WO2007021711A3 (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
MX2008002158A (en) Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands.
WO2002085853A3 (en) Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
MX2008013053A (en) Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands.
MXPA06000957A (en) N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826492

Country of ref document: EP

Kind code of ref document: A2